AUG 13, 2026 · PHASE 1 TRIAL
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
ClinicalTrials.gov
Phase 1b dose-escalation trial with no results reported; this is a registry record describing a planned study design, not outcome data.
Reported
Planned enrollment24
Study phasePhase 1b
Primary outcome measureMaximum tolerated dose, up to 28 days